Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FluBHPVE6E7 in HPV16-infected Women
NCT05829629Phase 1Recruiting
- Sponsor
- BlueSky Immunotherapies
- Start
- Sep 2023
- Primary completion
- Sep 2025
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in human papillomavirus infection, cervical intraepithelial neoplasia (CIN) and Squamous Intraepithelial Lesion (SIL) comparing FluBHPVE6E7 with Placebo (2 arms). Primary endpoint: Frequency and severity of adverse events at 7 days. Started Sep 2023; status: recruiting.
02
Drugs
FluBHPVE6E7
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)Squamous Intraepithelial Lesion (SIL)
Beyond the preview
Go deeper on NCT05829629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05829629.